ANVS earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -1.01. Updated 2026-07-23.
Annovis Bio (ANVS) Research Hub
Annovis Bio (ANVS) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.12 USD (-8.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.01, market cap 0.03B. This hub links to the full technical, earnings and options research available for ANVS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 1.12 USD (-8.20%) |
| 52-week range | 1.11 USD – 2.15 USD |
| Trend regime | Range |
| 14-day RSI | 12.7 (Oversold) |
| Trailing P/E | -1.01 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ANVS
Covered Call on ANVS: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANVS: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANVS: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
ANVS technical analysis: range, last 1.12 USD, RSI 12.7, 52w range 1.11 USD–2.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ANVS in?
Annovis Bio (ANVS) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is ANVS in an uptrend or downtrend?
As of 2026-09-11, ANVS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANVS's trailing P/E ratio?
ANVS's trailing P/E is -1.01, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does ANVS next report earnings?
ANVS is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.44 USD.